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Background/Purpose: Home parenteral nutrition (HPN) is being increasingly used to treat children with
intestinal failure. This study evaluated the long-term growth, outcome and complications in Taiwanese pediatric
patients with intestinal failure who were treated with HPN.
Methods: This retrospective study included 27 consecutive pediatric patients with intestinal failure who
received long-term HPN between 1987 and 2002. These patients were categorized into two groups according
to whether they had short bowel syndrome or a bowel motility disorder. Growth, prognosis and complications,
including cholestasis, hypoglycemia, hyperglycemia and infections were compared between the two groups.
Results: The median age of starting HPN was significantly younger in patients with short bowel syndrome (5
months) than in patients with motility disorders (1.9 years). The median duration of HPN treatment in the
overall group was 13.5 months (range, 2.1–113.1 months); weight and height increased 1.7 ± 2.3 and 1.0 ±
1.6 in z score, respectively. The most common complications were cholestatic liver disease (52%),
hypoglycemia (15%) and hyperglycemia (33%). All patients maintained stable serum glucose levels at follow-
up. Cholestatic liver disease developed after 2.3 ± 2.0 months of total HPN in 13 patients, which subsided
after 9.7 ± 6.9 months in 11 patients, while two patients died. The mean incidence of central venous infection
was 3.0 ± 3.3 per 1000 HPN days. The most common pathogens were Staphylococcus spp. (50%) and Candida
spp. (30.6%).
Conclusion: HPN treatment can successfully provide a bridge to enteral nutrition in pediatric patients with
intestinal failure. The metabolic disturbances and cholestasis are usually transient, but infection control is
important throughout the period of HPN treatment. [J Formos Med Assoc 2006;105(5):399–403]
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Intestinal failure is defined as the reduction in
functioning gut mass below the amount necessary
for adequate digestion and absorption of food.1
Total or partial parenteral nutrition (TPN, PPN)
via a central venous catheter is required in these
patients to maintain or obtain adequate growth.
The home parenteral nutrition (HPN) technique
was developed as an effective and feasible nu-
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trition supply route for those who require long-
term TPN.2 In children with intestinal failure,
HPN can aid in the transition from TPN to enteral
feeding.3–5 Encouragement of enteral nutrition
is very important to enhance intestinal adapta-
tion and to avoid irreversible gut failure.6 In pa-
tients with persistent intestinal failure, however,
long-term HPN may be needed until a good pro-
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Statistical analysis
The age at starting HPN, duration of HPN, out-
come and complications were compared between
patients with short bowel syndrome and patients
with motility disorders. Data were expressed as
mean ± standard deviation or median (range).
Statistical analysis was performed by the Mann-
Whitney U test, and paired data were compared
by the Wilcoxon signed rank test. The chi-square
test was used for categorical data. A p value < 0.05
was considered to indicate a significant difference,
and a p value < 0.1 a trend of difference.
Results
The short bowel syndrome group comprised 13
patients with an anatomically inadequate length
of bowel, either congenital or acquired after mas-
sive bowel resection. The bowel motility disorder
group comprised 14 patients who had an adequate
length of bowel anatomically, but had either me-
gram of small bowel transplantation is avail-
able. The purpose of this study was to evaluate
the prognosis, complications and duration of in-
testinal adaptation after HPN treatment.
Methods
The Total Parenteral Nutrition Support Team of
this hospital was established in 1987 to care for
patients receiving HPN support. Before implemen-
tation of this program, parenteral nutrition re-
quired a prolonged hospital stay. There were 33
pediatric patients who received TPN support via
central venous infusion at home between 1987
and 2002. Among them, six patients received HPN
for less than 2 months and were excluded from
this study. The characteristics of the remaining 27
patients are shown in Table 1. A complete HPN
program started from the insertion of either a
Hickmann or Broviac central venous catheter for
long-term use. The parenteral nutrition solution
contained glucose, amino acids, electrolytes and
trace minerals. Fat emulsion was administered
via a Y set with parenteral fluid. These patients re-
ceived continuous total or partial parenteral fluid
infusion with a constant infusion volume and
composition initially, tapered to 10–12 hours in-
fusion per day before discharge. Serum electro-
lytes, plasma glucose and liver enzyme activity
were monitored regularly. Before discharge from
hospital, the patients and their caregivers were
trained in the use of aseptic procedures and HPN
technique. The use of the HPN program was also
monitored at regular outpatient follow-ups.
Patients were divided into the short bowel syn-
drome group or the bowel motility disorder group
according to their underlying disease. Cholesta-
sis was defined as a serum total bilirubin level > 2
mg/dL with a pattern of conjugated hyperbiliru-
binemia. Two patients with cholestasis before HPN
treatment were excluded from the evaluation for
the complication of cholestatic liver disease. Fast-
ing serum glucose level > 126 mg/dL (7 mmol/L)
was defined as hyperglycemia, and < 50 mg/dL
was defined as hypoglycemia.
Table 1. Diagnoses in pediatric patients
receiving HPN
Diagnosis n (%)
Short bowel syndrome 13 (48)
Congenital 4
Necrotizing enterocolitis 3
Gastroschisis 3
Tumor s/p operation 2
Atresia s/p resection 1
Bowel motility disorder 14 (52)
Malrotation* 1
Multiple atresia* 1
Diaphragmatic hernia† 1
Tumor‡ 2
Hirschsprung disease§ 1
Neuronal dysplasia 1
Motility disorder 4
Eosinophilic enteropathy 1
Crohn’s disease 2
*Malrotation/multiple ileal atresia status after operation, with
poor wound healing and motility disorder; †diaphragmatic hernia
status after operation, complicated with ileus and fistula;
‡neuroblastoma and gastric cancer with intestinal obstruction;
§patient had symptoms of severe diarrhea postoperatively and
regained enteral nutrition within 1 year.
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chanical or functional bowel obstruction (Table
1). The median age at the start of HPN was 5
months (range, 2–13 months) in the short bowel
syndrome group, and 1.9 years (range, 4 months
to 15.75 years) in the bowel motility disorder
group. The median duration of HPN treatment was
13.5 months (range, 2.1–113.1 months), and was
not significantly different between the two groups
(Table 2).
During follow-up in the short bowel syndrome
group, four patients died, three continued to use
total or partial HPN, five successfully transitioned
to total enteral nutrition, and one was lost to fol-
low-up. In the bowel motility disorder group, two
patients died, two continued to use total or partial
HPN, nine successfully transitioned to total en-
teral feeding, and one was lost to follow-up. Of
the six patients who died, five died of shock, in-
cluding three (50%) with bacteremia and two
(33.3%) with fever of unknown origin. One pa-
tient (16.7%) died of obstructive airway disease
without infection. The 14 patients who success-
fully transitioned to total enteral nutrition discon-
tinued HPN therapy after  17.9 ± 22.3 months of
use. Weight increased significantly from –2.8 ±
2.4 to –1.2 ± 1.3 in z score, and height increased
from –3.0 ± 3.0 to –2.0 ± 2.3 in z score after HPN
treatment.
The most common complications of HPN
treatment were infection (63%), hypoglycemia
(15%), hyperglycemia (33%) and cholestatic liver
disease (52%). There was no association between
the incidence of complications and age. The inci-
dence of transient hypoglycemia was significantly
higher in patients with short bowel syndrome than
in patients with bowel motility disorders. The me-
dian age of the four patients with hypoglycemia
was 5 months (range, 3–8 months). There were
no significant differences in the frequency of oth-
er complications between the two groups. Four
of the patients with bowel motility disorders had
no complications during a median duration of
Table 2. Characteristics of patients and complications during home parenteral nutrition (HPN)
Short bowel syndrome Bowel motility disorder p
Patients, n 13 14
Male / Female 9/4 9/5 0.65*
Mean age of starting HPN, yr (range) 0.4 (0.2–1.1) 1.9 (4–15.8) < 0.001*
Mean HPN duration, mo (range) 015.5 (3.4–109.1) 0010.7 (2.1–113.1) *0.325
Prognosis, n *0.233
Died 4 2
Continued HPN usage 3 2
Enteral feeding 5 9
Lost to follow-up 1 1
Complications†
Free from complications 0 4 0.03*
Sepsis 100 7 0.06*
Hypoglycemia 4 0 0.01*
Hyperglycemia 3 6 0.16*
Cholestasis 8 5 0.05*
Sepsis rate (/1000 HPN days) 3.9 ± 4.2 2.1 ± 3.5 0.094
Outcome‡
Weight gain (z score) 1.4 (–2.6 ➔ –1.2) 1.9 (–3.0 ➔ –1.2) 0.720
Height gain (z score) .1.0 (–2.1 ➔ –1.3) .1.0 (–3.7 ➔ –2.8) 0.720
*p < 0.05; †hypoglycemia was defined as fasting serum glucose < 50 mg/dL, hyperglycemia as fasting serum glucose > 126 mg/
dL, and cholestasis as serum total bilirubin > 2 mg/dL; ‡weight and height before and after HPN treatment expressed in z score
for age in parentheses.
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HPN use of 6.2 months (range, 3.1–12.1 months).
All patients maintained stable serum glucose
levels before discharge from hospital. Cholestatic
liver disease developed after HPN treatment in 13
patients. Among them, 11 patients recovered, but
two died from sepsis and airway obstruction after
using HPN for 8 months and 1 year and 2 months,
respectively. Cholestatic liver disease developed at
2.3 ± 2.0 months after starting TPN, and recovery
occurred at 9.7 ± 6.9 months of use.
During a follow-up of 52.8 person-years of
HPN usage, 83 catheters were inserted in the 27
patients. Sixty-nine catheters were removed in
hospital. Eight catheters were removed due to HPN
discontinuation, and 61 were removed due to in-
fection (66%), occlusion (10%), leakage (3%)
and dislodgement (21%), as summarized in
Table 3. Microbacterial infection was found in
34 catheters, and 27 of them were removed. The
mean incidence of central venous infection was
3.0 ± 3.9 per 1000 HPN days. The most common
pathogens isolated in patients with bacteremia
were Staphylococcus spp. (50%) and Candida spp.
(30.6%), as shown in Table 4.
Discussion
Patients with short bowel syndrome comprise
the majority of patients who receive HPN treat-
ment, especially among children.6,7 The underly-
ing causes of short bowel syndrome are different
in children and adults. Congenital short bowel
or acquired short bowel due to necrotizing enter-
ocolitis, gastroschisis or atresia accounted for
about half of the patients who received HPN in
this series. The age at HPN treatment was signifi-
cantly younger in patients with short bowel
syndrome. The prognosis and incidence of com-
plications, however, was not different between
the short bowel syndrome group and the bowel
motility disorder group, except for hypoglycemia,
which was associated with younger age in the
short bowel syndrome group. The body weight
and height of patients in both groups significantly
improved after HPN treatment, especially body
weight which increased by 1.7 in z score. HPN is
the better choice for adequate nutritional support
in patients with intestinal failure. Infants and
children have greater potential for intestinal adap-
tation, which usually occurs within 3–12 months
and even up to 3 years.8,9 In this study, 14 patients
(52%) could achieve total enteral nutrition after
17.9 ± 22.3 months of HPN. This finding indicates
that HPN is a successful method for bridging to
Table 3. Reasons for catheter removal in
pediatric patients receiving home
parenteral nutrition
Reasons Catheters removed, n
Infection 400
Proven sepsis 260
Local infection 1
Fever or suspected sepsis 130
Persistent occlusion 6
Catheter dislodgement 130
Catheter leakage 2
Catheter no longer needed 8
A total of 69 catheters were removed in 27 patients.
Table 4. Etiology of bacteremia in pediatric
patients receiving home parenteral
nutrition
Organism Positive cultures, n
Staphylococcus spp. 180
Staphylococcus aureus 9
Staphylococcus epidermidis 6
Staphylococcus hominis 3
Gram-negative bacilli 7
Klebsiella pneumoniae 1
Escherichia coli 2
Acinetobacter spp. 2
Stenotrophomonas maltophilia 1
Corynebacterium spp. 1
Fungi 110
Candida parapsilosis 4
Candida guilliermondii 3
Candida albicans 3
Candida tropicalis 1
Thirty-six microorganisms were cultured in 34 catheters in 52.8
person-years; mixed infection was found in five catheters (4
catheters in the same patient).
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enteral nutrition in the majority of pediatric pa-
tients with intestinal failure.
As long-term HPN support is necessary in some
patients with persistent intestinal failure, avoid-
ing HPN-related complications becomes an even
more important issue.10 Catheter infection and
mechanical complications can be eliminated if
caregivers are familiar with aseptic procedures.
The infection rate in this pediatric series of 3.0
per 1000 HPN days is higher than in a previous
study in adults of 2.1 per 1000 HPN days.11 A low-
er incidence of infection was reported to be as-
sociated with longer HPN duration and the de-
lay between HPN onset and the first infection.12–14
The failure to identify any factors associated with
infection in this study may have been due to the
shorter duration of HPN use in children than in
adults, with many children successfully transition-
ing to enteral nutrition in the first 2 years. The
incidence of infection can be decreased further
through a good aseptic program for HPN.
Transient hypoglycemia was observed in four
patients in this series, all of whom were young-
er than 8 months. This observation indicates the
importance of blood glucose monitoring in in-
fants and younger children receiving HPN. The
prevalence of chronic cholestasis or complicated
HPN-related liver disease increased with longer
duration of parenteral nutrition, which was re-
ported in adult patients.15 In this study, 52% of
pediatric patients developed cholestatic liver dis-
ease after a mean duration of 2.3 months of HPN
treatment, but all recovered. This finding suggests
the high potential of children to develop and re-
cover from liver dysfunction during HPN.
In conclusion, HPN treatment can allow pedi-
atric patients with intestinal failure to achieve
adequate weight and height gain, and is a success-
ful and temporary method to regain enteral nutri-
tion in patients with intestinal adaptation. The
metabolic disturbances are mostly transient, and,
although cholestatic liver disease frequently deve-
lops, almost all children recover. Bacteremia is a
relatively common problem, and prevention of
sepsis is important throughout the period of HPN
treatment.
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